ロード中...
Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors
Dipeptidyl-peptidase-IV (DPP-4) inhibitors have become an important orally active drug class for the treatment of type 2 diabetes as second-line therapy after metformin failure or as monotherapy or combination therapy with other drugs when metformin is not tolerated or contraindicated. DPP-4 inhibit...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3666443/ https://ncbi.nlm.nih.gov/pubmed/23730503 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042018813486165 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|